Fabry disease: 2026 so far

It became clearer that lab marker changes may not match pain changes.

January reports described a placebo-controlled study showing that lucerastat lowered Fabry storage markers (lab measures linked to Fabry buildup) in blood and urine, but did not reduce neuropathic pain (nerve pain) over 6 months. Kidney function measures were similar between groups in the randomized portion. A longer-term open-label follow-up (everyone knows what they are taking) was described as exploratory. Nausea and diarrhea were reported more often with lucerastat, and no deaths were reported. This helps set expectations for how to read trial results when lab numbers improve but short-term symptom scores do not.

Research covered in: January 2026

Longer observational follow-up added patient-reported and biomarker context.

In the months covered, observational follow-up (non-randomized real-world reports) linked migalastat (in amenable variants) to reductions in lyso-Gb3 (a blood marker linked to Fabry storage) and generally stable kidney and heart measures at the group level. These same reports noted that some individuals still worsened or stopped because of side effects. In one French observational study, patient-reported data suggested perceived benefit often stayed clinically meaningful and stable over 2 years. A small subgroup who switched from ERT (enzyme replacement therapy, IV enzyme infusions) to migalastat reported higher benefit and satisfaction, without proving causality. Case reports added long-term tracking examples (including echocardiographic mass trends and corneal deposit changes) but cannot be generalized, which is important when comparing your own course with group averages.

Research covered in: April 2026, May 2026, August 2026

Early safety reports were followed by mixed and then stronger observational outcome links.

Early 2026 reports described add-on kidney/heart medicines in small or self-controlled datasets. This included dapagliflozin linked to lower urine albumin in a 16-person observational study, and SGLT2 inhibitors (diabetes medicines that can also affect kidneys and heart) appearing safe over 12 months in a real-world before/after comparison. By May, a matched retrospective analysis (13 vs 13) found no significant differences in heart ultrasound measures or lab markers with SGLT2 inhibitors. Urinary/low-volume symptoms were common, though discontinuation was uncommon. In September, a larger real-world matched analysis reported that SGLT2 inhibitor exposure was linked to lower rates of a combined outcome (death, heart attack, acute heart failure) and lower death risk at 2 and 5 years, but it was explicitly not randomized. These findings increased interest in add-on therapy, while still leaving uncertainty about cause-and-effect and which Fabry subgroups benefit.

Research covered in: February 2026, March 2026, May 2026, September 2026

Reports connected immune responses to infusion reactions and highlighted variable organ outcomes.

Several reports emphasized that enzyme replacement therapy (ERT; IV enzyme infusions) does not affect everyone the same way. Blood storage markers often fell, yet kidney outcomes ranged from stability to progression, even within families sharing the same GLA variant. Immune response was a practical management issue. Lab testing showed some patients had antibodies (immune proteins that can block a medicine) that inhibited infused enzyme activity, with patterns differing by sex and by ERT product. An observational study linked infusion-associated reactions to anti-drug antibodies. One center reported fewer infusion-associated reactions with a stepwise dose-escalation start to agalsidase beta (small prospective comparison), while antibody development still occurred. This points to why ERT follow-up may include both organ tracking and attention to infusion reactions and antibody patterns, rather than a single predictable response profile.

Research covered in: April 2026, June 2026, July 2026, August 2026, September 2026

More studies tied outcomes to combined ECG/imaging signals and progression speed.

In the months covered, studies repeatedly suggested that Fabry heart involvement is described best by combining different types of information rather than relying on one test. These domains included ECG (electrocardiogram, a heart rhythm tracing), echocardiography (ultrasound of the heart), cardiac MRI (heart MRI scan), and selected blood markers. Observational cohorts linked higher baseline structural involvement and faster worsening trajectories on imaging scores to higher risk of heart failure hospitalization or cardiovascular death. In a small single-center study, T2 mapping values were higher in scarred heart regions on MRIs where scar had newly appeared or grown, but only two comparisons reached statistical significance; the study did not establish whether the T2 changes preceded scar growth. Follow-up data also suggested electrical measures (for example, QRS duration, a timing measure on ECG) may worsen more clearly over time than some imaging measures in small cohorts. Combined ECG/echo indices also helped distinguish Fabry from amyloidosis (a protein-deposition disease) and hypertrophic cardiomyopathy (a thickened-heart-muscle condition) in thick-wall evaluations. This supports a monitoring approach that looks at patterns across tests and change-over-time when estimating heart risk.

Research covered in: February 2026, March 2026, June 2026, July 2026, August 2026, September 2026